Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

KalVista Pharmaceuticals (KALV) Change in Accured Expenses: 2014-2025

Historic Change in Accured Expenses for KalVista Pharmaceuticals (KALV) over the last 8 years, with Apr 2025 value amounting to $8.1 million.

  • KalVista Pharmaceuticals' Change in Accured Expenses rose 433.26% to $8.1 million in Q2 2025 from the same period last year, while for Apr 2025 it was $8.9 million, marking a year-over-year increase of 178.62%. This contributed to the annual value of $14.4 million for FY2025, which is 349.64% up from last year.
  • Latest data reveals that KalVista Pharmaceuticals reported Change in Accured Expenses of $8.1 million as of Q2 2025, which was up 61.11% from $5.0 million recorded in Q4 2024.
  • In the past 5 years, KalVista Pharmaceuticals' Change in Accured Expenses registered a high of $8.1 million during Q2 2025, and its lowest value of -$2.4 million during Q2 2024.
  • For the 3-year period, KalVista Pharmaceuticals' Change in Accured Expenses averaged around $2.1 million, with its median value being $2.9 million (2024).
  • Its Change in Accured Expenses has fluctuated over the past 5 years, first crashed by 43.23% in 2024, then surged by 433.26% in 2025.
  • Quarterly analysis of 3 years shows KalVista Pharmaceuticals' Change in Accured Expenses stood at $4.0 million in 2023, then grew by 25.49% to $5.0 million in 2024, then spiked by 433.26% to $8.1 million in 2025.
  • Its Change in Accured Expenses was $8.1 million in Q2 2025, compared to $5.0 million in Q4 2024 and -$1.8 million in Q3 2024.